See What HealthDay Can Do For You
Contact Us

Gene Profiling Improves Burkitt's Lymphoma Diagnosis

Identifying genetic signature for Burkitt's can help guide treatment

WEDNESDAY, June 7 (HealthDay News) -- Genomic technology can distinguish Burkitt's lymphoma from other B-cell lymphomas, guiding crucial therapy choices, according to research in the June 8 issue of the New England Journal of Medicine.

Harald Stein, M.D., of Charite Universitatsmedizin Berlin in Germany, and colleagues profiled gene-expression in 220 aggressive B-cell lymphomas, including eight Burkitt's lymphomas, generating a "molecular signature" for Burkitt's.

"Our molecular definition of Burkitt's lymphoma clarifies and extends the spectrum of the World Health Organization criteria for Burkitt's lymphoma," the authors write.

In another study, Sandeep S. Dave, M.D., of the National Cancer Institute in Bethesda, Md., and colleagues distinguished Burkitt's lymphoma from diffuse large-B-cell lymphoma by profiling gene expression in tumor biopsies of 303 aggressive lymphoma patients.

"Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma," the authors write.

In an editorial, Nancy Lee Harris, M.D., of Harvard Medical School in Boston, writes that the two studies show "the usefulness of gene-array analysis for defining biologic entities with important implications for clinical research and practice."

Abstract
Full Text (subscription or payment may be required)
Abstract
Full Text (subscription or payment may be required)
Editorial

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.